arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Amylyx Pharmaceuticals, Inc.

AMLX

$30.59 ▼ -2.38 (-7.22%) at close

6 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Amylyx Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.9B

Dividend Yield —

Revenue Growth N/M

Op. Margin None

ROIC -50.2% ↗

FCF / Share $-1.31 ↗

Trailing P/E —

Price / Book 11.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-144.74M

↑ +52.0% —

Operating Margin Operating profit as % of sales

-360.2%

↓ -3635.1% —

FCF / Share Free cash flow per share

$-1.31

↑ +47.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	N/M	-77.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1063%)	1612.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+20062%)	7700.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+96150%)	—	—
EPS Growth YoY (%)	65.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	74.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	52.0% Excellent Excellent Year-over-year change in net income	N/M	N/M	-125.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	47.0% Excellent Excellent Year-over-year change in free cash flow	N/M	N/M	72.7% Excellent Excellent Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	—	574.3% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Operating Margin (%) (%)	—	-360.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2501%)	10.2% Caution Caution Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-32%)	—	—	—
Effective Tax Rate (%) (%)	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	9.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	-345.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2978%)	12.9% Fair Fair Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+8%)	—	—	—
FCF Margin (%) (%)	—	-192.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	2.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.56x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.22x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-50.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-190.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	8.1% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	-59.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	43.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-46.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-162.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	7.5% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	-51.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-78.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-47.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-416%)	-183.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1321%)	11.4% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-24%)	-58.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-488%)	58.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+288%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-226.65M	$-77.39M	$-170.20M	$-62.53M	$-50.19M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$0.00	$1.28	$5.66	$0.38	$0.04	—
Basic EPS, GAAP (USD)	$-1.53	$-4.43	$0.73	$-3.39	$-13.35	—
Free Cash Flow per Share (USD)	$-1.31	$-2.46	$0.16	$-3.12	$-11.41	—
Book Value per Share (USD)	$2.78	$2.40	$6.40	$5.12	$-21.53	—
Tangible Book Value per Share (USD)	$2.78	$2.40	$6.40	$5.12	$-21.53	—
Basic Weighted Avg Shares (shares)	94.57M	68.14M	67.23M	58.50M	6.59M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$300.98M	$161.03M	$382.62M	$335.52M	$87.56M	—
Total Equity (USD)	$305.26M	$164.76M	$433.43M	$340.61M	$-151.17M	$-66.72M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$87.37M	$380.79M	$22.23M	$285.00K	—
Depreciation Expense (USD)	$525.00K	$904.00K	$1.09M	$487.00K	$52.00K	—
Net Income, GAAP (USD)	$-144.74M	$-301.74M	$49.27M	$-198.38M	$-87.93M	—
Operating Cash Flow (USD)	$-123.34M	$-167.65M	$11.92M	$-179.87M	$-74.80M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters

Amylyx Pharmaceuticals, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare AMLX with peers